This is a promotional webpage for UK and IE Healthcare Professionals, funded by Pharmacosmos UK Ltd.
Prescribing Information can be found at the end of this webpage. Adverse events should be reported. Reporting forms and
information can be found in the UK at www.yellowcard.mhra.gov.uk and in IE at www.hpra.ie.
Adverse events should also be reported to Pharmacosmos at pvuk@pharmacosmos.co.uk T: +44 1844 269 007
Ferric derisomaltose is marketed as Monover® in Ireland.
For patients ≥18 years for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly. The diagnosis must be based on laboratory tests.
IRONMAN - This investigator-led trial is the first long-term* study in iron deficient heart failure patients (HFrEF) demonstrating
The primary endpoint of recurrent hospitalisations for heart failure and cardiovascular death did not meet statistical
significance, however, pre-specified Covid sensitivity analysis showed nominal significance.
IRONMAN was funded by the British Heart Foundation and Pharmacosmos. Pharmacosmos provided supplies of ferric derisomaltose and
supported the trial with an additional unrestricted grant. National Health Service Greater Glasgow and Clyde and the University of Glasgow were cosponsors for the trial.
RRR 18%
(ARR 5.1%)
of hospitalisation for heart failure and cardiovascular death with Ferric derisomaltose vs Usual care (p=0.070)1
RRR 24%
(ARR 7%)
of hospitalisation for heart failure and cardiovascular death with Ferric derisomaltose vs Usual care (p=0.047) in prespecified Covid-19 sensitivity analyses1
2.7 years
median follow-up with serious adverse events, including infections, being on par or lower with Ferric derisomaltose vs Usual care1
ARR= Absolute Risk Reduction * the IRONMAN trial, > 1 year
1. Kalra et al, Lancet 2022
Ferric derisomaltose (FDI)
... to give your patients the iron they need in just ONE visit.*9
*Up to 20 mg/kg body weight
Useful FDI resources
See how FDI works - view the Mode of Action video.
Watch to find out more about IV iron-induced hypophosphataemia.
IV iron in obstetrics
Low interpregnancy interval can lead to chronic iron deficiency and anaemia.10,11
The downward spiral of iron deficiency and anaemia in pregnancy.
Figure adapted from Gupta, et al.10 and Millman N, et al.13
If iron stores are not restored soon after childbirth, then the adverse effects of post-partum iron deficiency/anaemia may continue into subsequent pregnancies.12
Interpregnancy interval <1 year increases risk of iron deficiency.13
Treatment with 1000 mg iron may not sufficiently replenish depleted stores, leading to a subtherapeutic response.*8,14
Addressing iron deficiency in a single visit minimises repeat visits and patient exposure to face-to-face interactions and the hospital environment.8
FDI is the only fast IV iron that can address IDA during pregnancy in single dose administrations of >1000 mg, up to 20 mg/Kg, based on booking/pre-pregnancy weight.†15,16
*1000 mg would only be correct dose for women with booking weight < 70 kg and Hb at least 100 g/l.
† FDI, like other IV irons, should not be used in the first trimester. Iron deficiency anaemia occurring in the first trimester of pregnancy can in many cases be treated with oral iron. FDI should not be used during pregnancy unless clearly necessary.9
In a study conducted to evaluate the IV iron service provided to pregnant women by the haemotology team at a single hospital, 121 pregnant women were retrospectively analysed in their 2nd or 3rd trimester and referred to the IV iron clinic during the audit period (September 2014 - April 2017)15
FDI was administered in single doses up to 20 mg/kg antenatal booking weight.15
FDI doses provided:15
- 108/121 patients (89.3%) received a single infusion of FDI, while 13/121 patients (10.7%) received two or three infusions
- The mean single FDI dose was 1173 mg, and 59.3% of patients received a dose >1000 mg
FDI increased Hb and ferritin levels in pregnant women with IDA15
59.3%
of women received a FDI dose >1000mg.15
89.3%
of women received one infusion of FDI.15
A single, high dose of FDI can address IDA during pregnancy, up to 20 mg/kg.15,16
IV iron in surgery
Pre-operative anaemia is associated with greater post-operative transfusion need, morbidity and mortality, (National Institute for Health and Care Excellence (NICE) Quality Standard 138).17
Up to 90% of patients may have anaemia after major surgery.18
Patient blood management (PBM) aims to minimise blood transfusion.19
- IV iron is an integral part of PBM - as an alternative to blood.19
NICE guidance:
Use of IV iron should be considered as an alternative to blood for peri-operative anaemia management.20
- Infusion of red blood cells has a role to play in the management of patients who are severely anaemic (Hb ≤70 g/l).21
- However, serious risks associated with blood transfusion include infection, fluid overload and incorrect blood transfusions being given.21
FDI is the only fast IV iron that can be administered in single doses >1000mg, up to 20mg/kg, giving you the potential to optimally treat patients prior to surgery.2
IV iron in
chronic kidney disease
In patients with chronic kidney disease (CKD), untreated anaemia is associated with reduced health-related quality of life and exercise capacity, and increased morbidity and mortality.22-24
In the majority of patients, 1000 mg of IV iron may not be sufficient to replete iron stores; 1500 mg may be more suitable for iron repletion in patients with iron deficiency anaemia.25
FDI allows administration of 1500 mg in a single infusion for patients weighing ≥75 kg.9